Skip to Content
Merck
HomeProductsPharma & Biopharma ManufacturingBioprocessing Cell CultureViral Vector Upstream Platforms

Viral Vector Upstream Platforms

Read more about

Gene therapies use viral vectors to introduce modified genetic material into cells. Manufacturing starts with the upstream production of viral vectors which are then purified and concentrated during downstream processing.  

The main challenges in upstream processing include productivity, product quality, process robustness, and scalability for commercial manufacturing. Our optimized upstream platforms minimize these challenges and are supported by technical and regulatory experts to help you make the right decisions at every step and stage of your process. 

Learn how to speed your viral vector-based cell and gene therapy development.

Request Information
Products
Loading

Our upstream platforms pair a cell line and cell culture medium, optimized for productivity. Although optimized to work together, each cell line and cell culture medium can be used independently. The platforms are supported with detailed protocols developed by our technical experts to achieve optimal performance, saving you time in process development and speeding delivery of your therapy to patients.

Key benefits of our cell lines:

  • GMP-banked, fully characterized and tested for adventitious agents
  • Licenses available for research or clinical/commercial use
  • Fully traceable and with documentation for regulatory filings

Key benefits of our cell culture media :

  • Chemically defined, animal component-free
  • GMP compliant manufacturing
  • Available in liquid and dry powder formats

Upstream Cell Lines and Cell Culture Media

THE VIRUSEXPRESS® LENTIVIRAL PLATFORM

For Saving Time in Process Development of Lentiviral Vector-Based Cell Therapies.

The VirusExpress® Lentiviral Platform is a transfection-based solution to lentiviral production challenges and offers a scalable upstream process optimized for suspension-based lentivirus production.

Key benefits of HEK293T VirusExpress® Cells

  • Cell line grows to high cell density and viability in suspension and has low doubling time
  • Selected for higher lentivirus production using PEI-based transient transfection method
  • GMP-banked, fully characterized and adventitious agent tested
  • Licenses available for research or clinical/commercial use.
  • Fully traceable and documentation available for regulatory filings

Key benefits of EX-CELL® CD HEK293 Viral Vector Medium

  • Supports high cell density and faster growth of HEK293T cells
  • Compatible with the PEI based transfection reagents used for viral production
  • Eliminates need for transfection step boost and enhancer reagents
  • Chemically defined, animal component-free
  • GMP compliant manufacturing
  • Available in liquid and dry powder formats

VirusExpress® Lentiviral Platform Performance

Request Information

THE VIRUSEXPRESS® AAV PLATFORM

For Saving Time in Process Development of HEK293 Cells Based  Gene Therapies.

The VirusExpress® AAV Platform offers a transfection-based solution to AAV production challenges, and an upstream process optimized for scalable, suspension-based AAV production.

Key benefits of HEK293 VirusExpress® Cells

  • Cell line grows to high cell density and viability in suspension and has low doubling time
  • Selected for higher AAV production using PEI-based transient transfection method
  • GMP-banked, fully characterized and adventitious agent tested
  • Licenses available for research or clinical/commercial use
  • Fully traceable and documentation available for regulatory filings

Key benefits of Cellvento® 4HEK Medium

  • Maximizes viable cell density and AAV productivity
  • Supports growth of multiple HEK293 cell lines with diverse nutritional requirements
  • Compatible with the PEI based transfection reagents used for AAV production
  • Chemically defined, animal component-free cell culture medium
  • GMP compliant manufacturing
  • Available in liquid and dry powder formats

VirusExpress® AAV Production Platform Performance

 

Request Information

THE Sf-RVN® PLATFORM

For Improving the Safety Profile of Your Insect Cell Based Gene Therapies.

Insect cell expression systems are an appealing alternative for AAV production as they are easy to cultivate and do not rely on transfection. However, as many Sf-9 insect cell lines are contaminated with Sf-Rhabdovirus, the Sf-Rhabdovirus negative Sf-9 cell line (Sf-RVN®) offers an improved viral safety profile and is an attractive option for scalable AAV production.

The Sf-RVN® Platform includes a Sf-Rhabdovirus-free cell line with enhanced risk mitigation, and provides a high-performance, scalable platform optimized for AAV production.

Key benefits of Sf-RVN® Insect Cell Line

  • A proven Sf-Rhabdovirus-negative Sf-9 cell line
  • Same characteristics as Sf-9 cells
  • GMP-banked, fully characterized and adventitious agent tested
  • Licenses available for research or clinical/commercial use
  • Fully traceable and documentation available for regulatory filings

Key benefits of EX-CELL® CD Insect Cell Medium

  • Optimized for growth and productivity of Sf-9 cells
  • Supports growth of multiple insect cell lines (Sf-21, S2, Tni and C636)
  • Chemically defined and animal component free
  • GMP compliant manufacturing
  • Available in liquid and dry powdered medium

The Sf-RVN® Platform Performance for Growth and AAV Production

Request Information

Related Product Resources

Related Videos

Slide 1 of 2
A healthcare professional is examining a smiling child wearing a purple shirt with a sun design, while another individual with their face obscured stands nearby, all against a yellow background.

SF-RVN® Platform

For Improving the Safety Profile of Your Bioprocesses

Illustration of DNA strands undergoing efficient clearance, surrounded by pink molecules against a light purple backdrop, symbolizing advanced molecular biology techniques.

Efficient DNA Clearance

Benzonase® nuclease efficiently digests DNA and RNA into fragments smaller than 5 base pairs.

Related Webinars

Slide 1 of 3
An open laptop with a colorful display featuring a stylized human figure in blue on the right and a pink rectangle on the left against a yellow background.

Driving the Viral Vector Expressway: Speeding Through AAV Manufacturing

The production of AAV viral vectors for gene therapy comes with unique upstream challenges. Learn how our HEK platform can solve these challenges.

An open laptop with a colorful display featuring a stylized human figure in blue on the right and a pink rectangle on the left against a yellow background.

Webinar Optimized VirusExpress® Production Technology

In this webinar, our upstream and downstream innovation scientists will explore how they optimized our VirusExpress® production technology for lentiviral vectors to maximize titer while providing a streamlined platform to accelerate development timelines to clinical trials.

An open laptop with a colorful display featuring a stylized human figure in blue on the right and a pink rectangle on the left against a yellow background.

Webinar: Addressing the Challenge of Scalability in Viral Vectors

The webinar covers the benefits of suspension cell-based processes, the use of chemically defined medium, complexities of the HEK293 and 293T cell lines, and the importance of scalability and manufacturability. Additionally, it discusses how a scalable templated process can expedite the transition from product development to commercialization.

Related Product Categories
Bioprocessing Cell Culture Media
Our off-the-shelf and customizable bioprocessing cell culture media (CCM) products enhance productivity in upstream mAb, vaccine, gene/cell therapy processes.
Bioprocessing Cell Lines
Our ready-to-use, off-the-shelf cell line systems greatly reduce the time, cost, and risk of developing new cell lines for production. Whether you are producing antibodies, recombinant proteins, or viral vectors for gene therapies, our cell line platforms can accelerate your upstream progress.
Bioprocessing Mobius® Single-Use Bioreactors
The Mobius® Bioreactor family includes the bench scale (2 mL and 3 L), pilot, clinical and commercial manufacturing (50 – 2,000 L) single-use bioreactors that enable cell culturing capabilities from early process development through commercial batch production.
Upstream Process Chemicals
Optimize biopharma processes: top-tier upstream chemicals for research to commercialization. Reliability, transparency, regulatory support assured.
Media Filtration
Safeguard bioreactors with effective cell culture media filtration. Choose the right filter for contamination prevention.
Related Applications
Viral Vector Upstream Processing
Complex upstream decisions in viral vector production affect downstream processes. Raw materials, media, and storage choices significantly impact outcomes.
Viral Vector Characterization & Biosafety
Gene therapy demands biosafety testing for product safety and process understanding before patient use.
Viral Vector Contract Development & Manufacturing
Specialized viral vector drug production requires costly expertise, mitigated by partnering with experienced contract manufacturers for safety and compliance.
Viral Vector Vaccine Mfg.
A templated process produces live vector vaccines. Challenges: yield loss, filtration, aggregation, scaling. Collaboration overcomes manufacturing hurdles.
mRNA Vaccines and Therapeutics Manufacturing
mRNA vaccine technology offers rapid development and scalable manufacturing for disease prevention.
Pharma & Biopharma Startup Hub
Your new molecule or therapy begins its journey here. Find solutions and resources to navigate your path to successful drug discovery, development, and commercialization.
Related Services
Emprove® Program
Confidently speed your way through the regulatory maze and fast track your new drug to market with the Emprove® Program. High-quality products, comprehensive documentation, and superior customer support facilitate your efforts in qualification, risk assessment, and process optimization.
Gene Therapy Process Development
With over 25 years of experience, we have the expertise to support robust process development of viral vectors for cell and gene therapies. Our process development strategies ensure that product quality and patient safety remain a top priority as your therapy progresses from discovery to commercialization.
Viral Vector CTDMO Services
Our viral and gene therapy manufacturing site in Carlsbad, California has produced over 1,000 batches of virus, meeting rigorous timelines for more than 20 years with a complete range of services, a state-of-the-art cGMP facility, and deep regulatory understanding.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?